Theravance Biopharma, Inc. (TBPH) financial statements (2021 and earlier)

Company profile

Business Address UGLAND HOUSE, SOUTH CHURCH STREET
GEORGE TOWN, GRAND CAYMAN, KY1-1104
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments293281505349501172255
Cash and cash equivalents81583788934511389
Short-term investments21122312726015660165
Receivables542912120
Inventory, net of allowances, customer advances and progress billings   17121013
Inventory   17121013
Prepaid expense107174518 
Other undisclosed current assets36221079358
Total current assets:393338533379529237275
Noncurrent Assets
Operating lease, right-of-use asset4347
Nontrade receivables 4 8   
Property, plant and equipment1613131081010
Long-term investments and receivables13512421005151
Long-term investments13512421005151
Restricted cash and investments1111111
Deferred costs      1
Other noncurrent assets2222211
Other undisclosed noncurrent assets 0    (1)
Total noncurrent assets:767027631116362
TOTAL ASSETS:469409560441639300338
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities48454342243536
Accounts payable759621910
Accrued liabilities261012858
Employee-related liabilities35282424141118
Interest and dividends payable46     
Deferred revenue1232
Debt 8     
Deferred revenue and credits0000
Contract with customer, liability43
Other liabilities      5
Other undisclosed current liabilities642712212515 
Total current liabilities:1241129963494941
Noncurrent Liabilities
Long-term debt and lease obligation274274225224223  
Long-term debt, excluding current maturities227226225224223  
Operating lease, liability4748
Liabilities, other than long-term debt22859401787
Deferred revenue and credits4455
Deferred revenue07
Contract with customer, liability26
Deferred rent credit  8
Other liabilities22125361332
Total noncurrent liabilities:27630228426424087
Total liabilities:4004133823262895748
Stockholders' equity
Stockholders' equity attributable to parent(304)(224)(52)115350243290
Common stock00000  
Additional paid in capital1,2231,025961914863565429
Accumulated other comprehensive income (loss)00(0)(1)(0)(0)(0)
Accumulated deficit(1,527)(1,249)(1,012)(798)(512)(322)(139)
Total stockholders' equity:(304)(224)(52)115350243290
Other undisclosed liabilities and equity373219230    
TOTAL LIABILITIES AND EQUITY:469409560441639300338

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues72736015494212
Revenue, net151894
Cost of revenue
(Cost of Goods and Services Sold)
   (1)(0)(2)(7)
Gross profit:7273601548405
Operating expenses(370)(325)(299)(276)(229)(224)(244)
Other undisclosed operating income   1027
Operating loss:(298)(252)(239)(260)(180)(182)(233)
Nonoperating income (expense)3812(3)111
Investment income, nonoperating   (8)  (1)
Other nonoperating income38125112
Interest and debt expense(60)(32)(10)(9)(1)  
Other undisclosed income from continuing operations before equity method investments, income taxes      1
Loss from continuing operations before equity method investments, income taxes:(355)(275)(237)(272)(181)(181)(231)
Income from equity method investments683411    
Loss from continuing operations before income taxes:(287)(242)(226)(272)(181)(181)(231)
Income tax expense (benefit)9511(14)(10)(1)(6)
Net loss available to common stockholders, diluted:(278)(236)(216)(285)(191)(182)(237)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(278)(236)(216)(285)(191)(182)(237)
Comprehensive loss:(278)(236)(216)(285)(191)(182)(237)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)01(0)(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(278)(236)(215)(286)(191)(182)(237)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: